PTGX Q2 2018 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M

Gross Profit

$12M100.0% margin

Operating Income

-$9M-79.1% margin

Net Income

-$9M-74.2% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+8.3%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$137M

Total Liabilities

$30M

Stockholders' Equity

$108M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$0	—
Gross Profit	$12M	$0	—
Operating Income	-$9M	-$15M	+38.9%
Net Income	-$9M	-$15M	+42.2%

Revenue Segments

License And Collaborative Revenue

$12M100%